Skip to main content
Atrás
Watch Compare

Acurx Pharmaceuticals, Inc.

Calidad de datos: 83%
ACXP
Nasdaq Manufacturing Chemicals
$2.61
▼ $0.08 (-2.97%)
Cap. Mercado: 7.66 M
Precio
$2.68
Cap. Mercado
7.66 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -6.79 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-221.19%
Below sector avg (-53.34%)
ROIC-178.80%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Valoración

PE (TTM)
-0.96
Above sector avg (-1.47)
P/B Ratio2.11
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -1.0 -1.5
P/B 2.1 1.6
ROE % -221.2 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

3 analistas
Buy
Actual
$2.61
+551.3%
Objetivo
$17.00
$10.00
$10.00
$31.00
Pronóstico
P/E Futuro -1.19
EPS Futuro -$2.20
Ingresos Est. 0.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$2.20
-$2.55 – -$1.85
 0.0 2
FY2026 -$2.39
-$2.68 – -$2.10
 0.0 2

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$1.00 -$0.31 +68.8%
Q32025 -$1.49 -$1.23 +17.2%
Q22025 -$2.10 -$1.89 +10.0%
Q12025 -$2.80 -$2.20 +21.4%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7.97 M
ROE -221.19% ROA -130.49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6.79 M
ROIC -178.80% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value 3.64 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.96 Forward P/E N/A
P/B Ratio 2.11 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -88.65%
Market Cap 7.66 M Enterprise Value 7.66 M
Per Share
EPS (Diluted TTM) -5.32 Revenue / Share N/A
FCF / Share -2.38 OCF / Share -2.38
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85.20%
SBC-Adj. FCF -8.09 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -7.97 M -14.10 M -14.58 M -12.09 M -12.75 M
EPS (Diluted) -5.32 -0.87 -1.15 -1.12 -1.49
Gross Profit — — — — —
Operating Income -8.09 M — — — —
EBITDA — — — — —
R&D Expenses 1.83 M 5.40 M 6.04 M 4.75 M 2.03 M
SG&A Expenses — — — — 208,270.0
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.69 M 3.86 M 7.71 M 9.38 M 13.25 M
Total Liabilities 2.42 M 3.24 M 3.04 M 2.06 M 843,909.0
Shareholders' Equity 5.27 M 615,121.0 4.67 M 7.32 M —
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets — — — — —
Current Liabilities 2.42 M 3.24 M 3.04 M 2.06 M 843,909.0